Loading organizations...
Key people at Baxalta.
Baxalta is a Bannockburn, Illinois-based biopharmaceutical company that develops, manufactures, and commercializes specialized therapies for rare diseases, hematology, immunology, and oncology. Operating globally across more than 100 countries, the enterprise maintains 12 advanced biological manufacturing facilities, including a $1 billion Georgia plant, and employs approximately 16,000 people worldwide. Prior to its acquisition, the organization generated roughly $6 billion in annual revenue through the commercial sale of specialized biologic treatments, including hemophilia therapeutics and primary immunodeficiency products. The business was acquired by Shire plc for $32 billion in 2016, and its product portfolio was subsequently absorbed by Takeda Pharmaceutical Company following a $62 billion merger in 2019. Baxalta was founded in July 2015 under the leadership of chief executive officer Ludwig Hantson as an independent public spin-off from its former parent company, Baxter International.
Baxalta Incorporated was a biopharmaceutical company focused on developing, manufacturing, and marketing therapies for rare and chronic conditions, including hemophilia, immunology, oncology, bleeding disorders, immune deficiencies, alpha-1 antitrypsin deficiencies, burns, shock, and acute lymphoblastic leukemia[1][2][3]. It offered key products like ADVATE (recombinant factor VIII for hemophilia A), FEIBA (inhibitor management therapy), GAMMAGARD LIQUID (antibody-replacement for primary immunodeficiency), Hyqvia (immune globulin infusion for primary immunodeficiency), and Obizur (for acquired hemophilia A), serving patients with unmet medical needs in these areas[1][2]. Launched as a $6 billion independent entity in 2015 via spin-off from Baxter International, Baxalta emphasized sustainable supply, innovation through acquisitions, and expanding into gene therapy and oncology[2][3][4].
Baxalta originated as the biopharmaceutical division of Baxter International Inc., with Baxter announcing the separation in March 2014 to create two focused companies: one for biopharma (Baxalta) and one for medical products (retaining the Baxter name)[2][3][4]. Incorporated in Delaware on September 8, 2014, and headquartered in Bannockburn, Illinois, it became independent on July 1, 2015, through a pro rata distribution of 80.5% of its shares to Baxter shareholders, with Baxter retaining 19.5%[1][3]. Early milestones included 2010 licensing of Glassia for alpha-1 antitrypsin deficiency from Kamada Ltd., 2013 acquisition of hemophilia assets from Inspiration BioPharmaceuticals and Ipsen, and 2014 U.S. approval of Obizur[2]. Trading began on NYSE under BXLT on launch day, building on Baxter's legacy in recombinant therapies for hemophilia and rare blood disorders[3][4][5].
Baxalta rode the trend of biopharma spin-offs for focused innovation in rare diseases and biologics, capitalizing on growing demand for orphan drugs amid rising hemophilia and immunodeficiency prevalence[2][3][4]. Timing aligned with 2010s biotech boom, post-recombinant tech advancements, enabling niche expansion into gene therapy and oncology platforms amid favorable market forces like regulatory incentives for rare conditions[3][5]. It influenced the ecosystem by sustaining Baxter's hemophilia leadership, boosting supply for underserved patients, and modeling pure-play biopharma models that spurred sector M&A[2][4].
Post-2015 launch, Baxalta's trajectory shifted dramatically: Shire plc acquired it in 2016 for $32 billion, integrating its hemophilia and immunology assets into a larger rare disease powerhouse, with BXLT delisted[extrapolated from incorporation context; note: search results end at 2016 SEC filing]. Looking ahead from 2015 vantage, trends like gene therapy maturation and orphan drug pricing pressures would shape successors, evolving Baxalta's influence into broader Takeda (post-Shire acquisition) pipelines for sustained rare disease impact—reinforcing its role as a biopharma innovator from spin-off origins.
Key people at Baxalta.
